PRO 140

Drug Profile

PRO 140

Alternative Names: PA-14; PRO-140

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Progenics Pharmaceuticals
  • Developer CytoDyn; Progenics Pharmaceuticals; The Scripps Research Institute
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • Phase II/III HIV-1 infections
  • Phase II Graft-versus-host disease
  • Preclinical Breast cancer

Most Recent Events

  • 30 Jul 2018 The independent Institutional Review Board (IRB) announces clearance of a phase III trial for HIV infections in USA
  • 16 Jul 2018 Updated efficacy and safety data from the phase II/III CD02 trial in HIV infections released by CytoDyn
  • 16 Jul 2018 CytoDyn plans to conduct phase II trials in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top